Epidermal growth factor receptor pathway mutations and colorectal cancer therapy

Area of Science:

• Oncology
• Molecular Pathology
• Genomics

Background:

• Anticancer therapy is increasingly incorporating molecular analysis alongside traditional methods.
• Molecular tumor testing provides diagnostic and therapeutic insights, crucial for personalized medicine.
• Specific mutations in colorectal cancer predict resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy.

Purpose of the Study:

• To review key mutations influencing metastatic colorectal cancer treatment decisions.
• To identify emerging mutations for enhanced prognostic accuracy.
• To offer practical guidance on specimen submission for molecular analysis.

Main Methods:

• Systematic review of peer-reviewed literature on clinical trials and mutation analysis.
• Analysis of molecular mechanisms of drug resistance.
• Inclusion of comprehensive review articles and College of American Pathologists testing recommendations.

Main Results:

• Molecular analysis of colorectal cancer is now a prerequisite for anti-EGFR therapy.
• Identified mutations directly impact treatment choices and patient prognosis.
• Understanding specific mutations is vital for predicting therapy efficacy.

Conclusions:

• Mandatory molecular testing for colorectal cancer is critical before anti-EGFR therapy.
• Knowledge of predictive mutations enhances treatment selection and patient outcomes.
• Careful specimen selection and molecular analysis optimize patient care.